Physician profile
Manuel Tapia
NPI 1740572106
$5,120.28
in general payments reported to CMS, 2019-2025
31 companies · $973 in 2025
The $973 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $317 · 2021: $192 · 2022: $386 · 2023: $1,194 · 2024: $871 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.58 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,120.35 | 2019-2024 | Xarelto |
| Pfizer INC. | $516.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $509.45 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.45 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $314.48 | 2019-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $285.30 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $235.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.08 | 2019-2025 | Jardiance |
| Amgen INC. | $191.80 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $173.12 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $162.49 | 2022-2025 | Watchman Flx, General - Therapies |
| Heartflow, INC. | $142.05 | 2023-2025 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $127.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.09 | 2023-2025 | |
| Novo Nordisk INC | $75.40 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $60.67 | 2024 | Arcalyst |
| Astellas Pharma US INC | $58.51 | 2019 | |
| Kestra Medical Technology Services, INC. | $56.14 | 2024-2025 | Assure Wcd |
| Chiesi USA, INC. | $47.68 | 2019 | |
| Abbott Laboratories | $46.25 | 2023-2025 | Mitraclip, Xience Skypoint |
| Lexicon Pharmaceuticals, INC. | $44.79 | 2023-2024 | Inpefa |
| Tactile Systems Technology INC | $28.39 | 2021-2022 | |
| Scpharmaceuticals INC. | $25.40 | 2025 | |
| Medtronic, INC. | $22.65 | 2025 | Aurora Ev-Icd Mri Surescan |
| Terumo Medical Corporation | $22.52 | 2025 | Metacross Otw, Glidewire |
| Esperion Therapeutics, INC. | $19.91 | 2023 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $16.90 | 2023 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $14.90 | 2025 | Attruby |
| Lundbeck LLC | $14.63 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.19 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Tapia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.